The Remedy Room — AbilityForge Framework
The AbilityForge Framework
Original legislative architecture drafted by Michael Kissling. These are not bills someone else wrote that AbilityForge is tracking — these are proposals, frameworks, and evidentiary records authored here, designed to close the gaps the existing legislation leaves open.
Framework Sections
- The Clinical Integrity & Patient Safety Amendment
- ↳ The Equal or Better Mandate — Legal Promise vs. Documented Reality
- ↳ Denial Defensibility Score — 2023 vs. 2024 Carrier Comparison
- § 6 Buffer Fund Economic Simulator — Interactive Model
- Denial on Trial — A Framework for Medical Due Process
- The PSI Briefing — Documented Evidence of Prior Knowledge Omission
The Clinical Integrity & Patient Safety Amendment
Proposed Addition to S.3829 — Drafted by Michael Kissling, AbilityForge.net
⚡ The Critical Bolt
The entire Wrongful Denial Echo Chamber operates because the physician who signs the denial letter faces no personal professional consequence. A corporate reviewer can exclude objective clinical data on procedural pretexts, issue a denial the IRE will overturn in seconds, and walk away with their license intact. The Clinical Integrity Amendment closes this gap by making every IRE overturn a self-executing referral to the State Medical Board. This is not additional bureaucracy — it is the equivalent of bar discipline for an attorney who hides exculpatory evidence. The mechanism only works when the person pulling the trigger can lose their license for doing so.
The legal mandate — 42 CFR § 422.100
Medicare Advantage plans must provide coverage equal to or better than Traditional Medicare.
In exchange for this obligation, MA plans receive capitated federal payments averaging ~$1,000/month per enrollee — billions in taxpayer-funded premiums paid on the assumption that this legal standard is being met.
Traditional Medicare — the baseline
Denial defensibility
71.3%
of denials upheld by independent review · FY2022
Appeals overturned
28.7%
of appealed denials reversed · FY2022
DMEPOS / prosthetics
63.9%
overturned in prosthetic/equipment category · FY2022
Medicare Advantage — the reality
Denial defensibility
18.3%
of denials upheld by independent review · KFF 2023
Appeals overturned
81.7%
of appealed denials reversed · KFF 2023
PA volume
49.8M
prior auth requests · 2023 · averaging 4+ per enrollee/yr
The compliance gap — required vs. documented
Required floor
≥ 71.3%
defensibility
↔
Documented
18.3%
industry avg · 2023
Medicare Advantage defensibility falls 53 points below the Traditional Medicare baseline the law requires it to meet or exceed. This is not a data anomaly — it is a documented, multi-year, multi-carrier pattern of systematic non-compliance.
If 81.7% of MA prior authorization denials are overturned by a neutral physician — and the legal standard requires coverage equal to or better than Traditional Medicare, where only 28.7% are overturned — then the majority of Medicare Advantage denials are not coverage disputes. They are compliance failures.
Sources: 42 CFR § 422.100 · KFF Medicare Advantage prior authorization analysis 2023 · CMS Prior Authorization and Pre-Claim Review Program Stats FY2022 · DMEPOS = Durable Medical Equipment, Prosthetics, Orthotics, and Supplies
Full IRE overturn data → Room I
The KFF dataset, carrier-by-carrier overturn rates, and the 8-in-10 documentation are in The Problem Room.
Systemic Denial Practices →§ 1 — Prohibition of Prior Knowledge Omission
When a Medicare Advantage organization or ERISA plan has previously approved a specific functional classification, medical baseline, or K-Level, that classification becomes an Established Medical Fact for a minimum of 12 months.
In plain English: If UHC acknowledges a patient's K3 functional mobility status in March, it may not deny a permanent prosthetic in September by claiming the same mobility threshold is unmet — unless it produces new clinical evidence of decline. A denial issued against a prior-established medical fact without documentation of regression is void ab initio and triggers Buffer Fund penalties.
This provision directly addresses the documented Kissling v. UnitedHealthcare case: UHC approved K3 status in March 2023, then denied the permanent prosthetic in September 2023 while possessing that prior knowledge — a textbook Prior Knowledge Omission.
§ 2 — The Clinical Integrity Rule (The "Act 146 Standard")
Any adverse benefit determination based on medical necessity must be reviewed by a physician holding current, valid Board Certification in the same or directly relevant specialty as the treating physician. The reviewing physician must certify under penalty of perjury that they have reviewed all objective clinical data submitted — including PT/OT evaluations, imaging, and standardized assessment scores.
- A pediatrician may not review an adult bariatric claim.
- A general practitioner may not review a specialized prosthetic claim.
- A non-vascular physician may not review a vascular surgical necessity determination.
- An ocular plastic surgeon may not review a lymphedema surgery for a breast cancer patient.
That last example is not hypothetical. See Dr. Elizabeth Potter's documented peer-to-peer call in the Independent Voices section below.
§ 3 — The Patient Safety Buffer Fund
Upon submission of a medical necessity override by the treating physician, coverage is provisionally granted through the Patient Safety Buffer Fund while the determination is under review. Patients shall not be denied care during the appeals process.
If the denial is upheld:
The treating provider repays the Buffer Fund in full.
If the denial is overturned:
The insurer reimburses the Buffer Fund at 300% of the claim rate. The insurer funds the safety net their denials require.
§ 4 — The Administrative Cure Mandate
A plan may not issue a final denial for administrative reasons without first providing a 48-hour Cure Period to correct any clerical or procedural deficiency. If a plan classifies a denial as "administrative" to circumvent the Clinical Integrity review — when the record contained sufficient clinical data to warrant medical review — the plan faces a civil monetary penalty of $10,000 per violation.
This closes the loophole by which insurers reject claims on paperwork pretexts to avoid the specialty-matching and data-review requirements of § 2. In the 2023 KFF data, "Administrative reason" accounted for 18% of all ACA Marketplace denials — second only to the vague "Other" category.
Denial defensibility score
% of denials held up by independent review
Higher = the denial was medically defensible. Think of it as a test score — graded by a neutral examiner with no financial stake in the outcome.
Medicare
average
Group
The 2024 industry "improvement"
The industry average rose 1 point — carried almost entirely by UHC moving below the average. Centene and CVS/Aetna both got worse. The headline masks the divergence.
DMEPOS — prosthetics category
In Traditional Medicare, prosthetic denials are already among the hardest to defend — 63.9% overturned (FY2022). In Medicare Advantage, that number is substantially higher.
Sources: KFF Medicare Advantage prior authorization analysis 2023 & 2024 · CMS Prior Authorization and Pre-Claim Review Program Stats FY2022
Echo chamber context → Room I
The business model that depends on patients not appealing. The 0.2% appeal rate. The full carrier breakdown and the 8-in-10 documentation.
Systemic Denial Practices →§ 5 — Physician Accountability: The Malpractice Trigger
This is the critical section. The bolt that disassembles the chamber.
Any physician acting as a medical director or reviewer who issues a denial that is subsequently overturned by an IRE — due to a demonstrable failure to adhere to established clinical standards or failure to review submitted evidence — shall be deemed to have engaged in Unprofessional Conduct.
- Mandatory Board Reporting: The IRE shall be statutorily required, upon issuing an overturn, to report the name and license number of the reviewing physician to their respective State Medical Board for investigation into malpractice and negligence.
- Pierce the Corporate Veil: Reviewing physicians shall not be shielded from personal liability for patient harm caused by denials issued in contradiction to established medical consensus — regardless of their employment relationship with the plan.
"A prosecutor who hides exculpatory evidence faces disbarment. A corporate reviewer who ignores qualifying clinical data faces nothing — until now."
— Clinical Integrity & Patient Safety Amendment
The industry average IRE overturn rate is 81.7% (KFF 2023). UnitedHealthcare's rate was 85.2% in 2023, improving to 79.1% in 2024 under sustained public and legal pressure — credit where it is due. Neither number changes the structural argument. These are not medical disagreement rates. They are compliance failure rates — executed by physicians whose licenses have never been at risk. This single provision changes that calculus permanently, regardless of what direction the numbers move next.
§ 5 — the accountability gap
Same act. Two physicians. Two outcomes — until now.
The act: reviewing physician willfully omits qualifying clinical evidence — the IRE overturns the denial — a patient is harmed.
Treating physician
Misses or ignores clinical evidence. Patient harmed.
Consequence
- Malpractice liability
- State Medical Board review
- License suspension or revocation
- Wrongful death suit
- Criminal exposure
Insurance reviewer — today
Omits qualifying evidence. IRE overturns. Patient harmed.
"Corporate decision."
No personal liability
ERISA shield engaged
License never at risk
No board referral
No exposure
AMA 2024 — documented outcomes
29% of PA cases — serious adverse event
18% — life-threatening or permanent impairment
8% — disability, permanent damage, or death
Clinical Integrity Amendment — § 5
Same act. Same omission. Same outcome for the patient.
Consequence — same standard
- Mandatory board referral on IRE overturn
- License suspension or revocation
- Veil pierced — personal liability
- Malpractice exposure
- Criminal exposure via S.3829
UHC prior auth IRE overturn rate
2023 (KFF)
85.2%
2024
79.1%
UHC's 2024 rate reflects a genuine improvement — credit where it is due.
When UHC increased approvals under public pressure, shareholders sued them for it. There is no neutral equilibrium in a system without personal accountability.
Industry average overturn rate
2023 (KFF)
81.7%
Even at UHC's improved 2024 rate — nearly 8 in 10 appealed denials are still overturned.
§ 5 is not contingent on whether a carrier is having a good year. The structural accountability gap exists regardless of the number.
"A prosecutor who hides exculpatory evidence faces disbarment. A corporate reviewer who ignores qualifying clinical data faces nothing — until now."
— Clinical Integrity & Patient Safety Amendment, § 5 · AMA patient harm data: 2024 Prior Authorization Physician Survey (n=1,000)
§ 6 — Buffer Fund Sustainability and Long-Term Capitalization
The Patient Safety Buffer Fund is designed to be self-sustaining through the penalty revenue generated by wrongful denials. This creates an honest design paradox: the better the reform works, the less fraud feeds the fund. § 6 addresses this directly — not by hiding the problem, but by building a funding architecture that scales with success rather than depending on ongoing failure.
Phase 1 — Seed Capitalization (Year 0)
A one-time industry assessment of 0.1–0.2% of annual premium revenue across all participating carriers shall provide initial capitalization — estimated at $5–10 billion based on current denial volume and premium data. This is not a tax on patients. It is a one-time accountability deposit from the industry whose practices created the need for the Fund in the first place.
Phase 2 — Endowment Layer (Upon Reaching Critical Mass)
Once the Fund reaches its actuarially-modeled critical mass threshold — as determined by the Department of Recovery based on projected overturn volume and provisional coverage obligations — 20–30% of the Fund shall be carved into a low-risk investment portfolio (U.S. Treasuries and index instruments). The yield from this endowment becomes a perpetual baseline: at 4% annual return on a $2B corpus, the Fund generates approximately $80 million per year indefinitely — sufficient to cover residual provisional coverage when wrongful denials are rare. Success finances itself.
Phase 3 — Dynamic Multiplier Scaling (Triennial Adjustment)
The 300% reimbursement multiplier and 500% clawback penalty shall be subject to automatic triennial review by the Department of Recovery. Multipliers shall adjust downward as national wrongful denial rates fall:
The Department of Recovery's aggregated cross-case pattern data — already mandated by the legislative architecture — provides the exact dashboard needed to calculate and publish these adjustments transparently every three years. The scaling is not discretionary; it is automatic and public.
The Design Principle
Most enforcement funds assume the problem they are designed to solve will persist indefinitely. The Buffer Fund assumes the opposite — that the reform will work, and builds a funding architecture that proves it. When the multipliers scale down, it is not a sign of weakness. It is the actuarial signature of a system that no longer needs to punish its way to solvency. The burden of funding this safety net belongs entirely on the industry whose conduct made it necessary — not on the patients it was built to protect. The Department of Recovery publishes the data. Congress reads it. The public sees it. That transparency is the accountability mechanism that makes the whole architecture trustworthy.
§ 6 Buffer Fund Economic Simulator
Slide the denial rate to watch the Dynamic Multiplier Scaling engage in real time. This is the math behind § 6 — the architecture that funds itself.
Slide left to simulate the market correcting its behavior over time.
Default: the denied iliac vein stenting — $55,000.
Buffer Fund Reimbursement
$165,000
300% Multiplier
Clawback Penalty
$275,000
500% Multiplier
Total Insurer Liability
$440,000
Upon IRE overturn — capital flowing into the Fund
Multiplier thresholds per § 6 Dynamic Scaling schedule: >20% / 5–20% / <5%
Denial on Trial — A Framework for Medical Due Process
Proposed by Michael Kissling, AbilityForge.net | In support of S.3829 and the Clinical Integrity & Patient Safety Amendment
The Core Problem: A Rigged Proceeding
The current insurance appeals system asks patients to prove they deserve care — while the insurer who denied them controls the evidence, employs the reviewing physician, and faces no consequence if they are wrong. This is not a medical judgment system. It is a financial extraction system dressed in clinical language.
The Denial on Trial framework applies the logic of Gideon v. Wainwright to healthcare: you cannot have a fair proceeding when one side has no counsel. The current IRE system asks a single body to be both judge and patient advocate simultaneously — structurally identical to the injustice that created the public defender system.
Current System vs. Denial on Trial Model
| Role | Current System | Denial on Trial Model |
|---|---|---|
| IRE Role | Neutral arbitrator | Patient advocate (Public Defender) |
| Burden of Proof | Patient must prove need | Insurer must prove denial is justified |
| Medical Evidence | Reviewer may exclude data outside their note | All submitted clinical data reviewed under penalty of perjury |
| Ruling Authority | IRE acts as judge and advocate simultaneously | Administrative Law Judge rules independently |
| Physician Accountability | No consequence for wrongful denial | Mandatory State Medical Board referral on IRE overturn |
| Fraud Mechanism | Prior Knowledge Omission goes unpunished | Suppression of known qualifying evidence = malpractice trigger |
The Three Roles
- Prosecution (The Insurer): Files the denial — and bears the burden of proving it is justified against the established medical record.
- Public Defender (The IRE): Advocates for the patient's complete clinical record against that denial — as a Public Defender, not a neutral arbitrator.
- Adjudicator (Administrative Law Judge): Rules independently — with authority to trigger financial penalties and mandatory board reporting.
The Capacity Problem: Why We Need a Department of Recovery
S.3829's higher stakes — 300–500% clawbacks, mandatory board reporting, malpractice triggers — will cause insurers to fight every case harder. The current IRE infrastructure, already under strain, will be overwhelmed.
Private IREs rule case by case. They do not aggregate patterns. They do not notice that a single reviewing pediatrician is adjudicating hundreds of adult bariatric claims monthly. A federally-staffed Recovery Coordination Office would:
- Absorb IRE overflow volume created by the new penalty structure
- Maintain cross-case pattern data that converts individual fraud into prosecutable systemic fraud
- Administer the Patient Safety Buffer Fund with federal accountability
- Feed the mandatory board reporting pipeline the Clinical Integrity Amendment requires
"Long after the sensationalism of a verdict fades, the legislative reform that finally dismantles the Wrongful Denial Echo Chamber is what will endure."
— Michael Kissling, AbilityForge.net
The PSI Briefing — Documented Evidence of Prior Knowledge Omission
Submitted to the Senate Permanent Subcommittee on Investigations | March 2026 | Michael Joseph Kissling, Medicare Advantage Beneficiary & Healthcare Advocate
85.2%
UHC prior auth overturns
(KFF 2023)
81.7%
Industry average
overturn rate
~29%
Traditional Medicare
overturn rate
$1.1M+
Taxpayer cost
— this case alone
This is not a dispute over medical judgment. It is a documented mechanism of deceptive business practice — executed with paper trail proof of intent.
The Fraud Mechanism: Prior Knowledge Omission
UHC medical directors deny legitimate claims by deliberately ignoring qualifying medical information already in their possession. This is not administrative error. It is documented, repeatable policy.
- The insurer acknowledges a patient's qualifying status through an approval decision
- The insurer then denies a directly related claim while possessing that prior knowledge
- The reviewing physician excludes objective clinical data on procedural pretexts
- The patient is forced through an appeals process that functions as a delay weapon
- The insurer offloads the financial cost of resulting harm onto taxpayers
The Documented Case: Kissling v. UnitedHealthcare — The Paper Trail
UHC approves learner prosthetic — officially acknowledging K3 functional mobility status (AMPnoPRO score: 35). This classification is mandatory knowledge in UHC's possession.
Six days after K3 establishment: UHC changes beneficiary's plan, making all existing physicians and physical therapists out-of-network. Care continuity disrupted.
UHC denies transition to permanent tertiary prosthetic — claiming beneficiary does not demonstrate sufficient functional ability. Denial issued while UHC possesses K3 approval AND updated K4 PT evaluation (AMPnoPRO: 44/47).
Updated PT evaluation confirms advancement to K4 status (AMPnoPRO: 44/47). UHC reviewer explicitly refuses to acknowledge this data because it was not written in his specific office note.
UHC final denial letter states: "Medicare Guidance says that the requested computerized knee advanced feet exceed your needs" — a statement made with documented prior knowledge that patient was K3-K4, in direct violation of Medicare Policy Article A52496.
Maximus Federal Services (IRE) immediately overturns UHC denial. Finding: medically necessary. This overturn is equivalent to summary judgment — UHC's position was indefensible.
Medicare lowers microprocessor knee standard from K3 to K2 — meaning the patient would have qualified under even the future relaxed standard. UHC's denial had no medical or regulatory basis at any point in time.
The Smoking Gun: Dr. Stockhausen's Documentation
The attending physician, Dr. Sean T. Stockhausen, documented in writing that the UHC peer-to-peer reviewer confirmed he remembered the K4 argument — and then stated he could not use objective PT data, including walking speed and AMPnoPRO score, unless it was written directly in his own office note. He subsequently amended his office note specifically to include the AMPnoPRO score.
This is the echo chamber mechanism documented by the treating physician himself: standardized, Medicare-approved assessment scores excluded on a procedural pretext manufactured by the corporate reviewer. Under the Clinical Integrity Amendment § 2, this action would be void and trigger mandatory board reporting.
The Cascading Taxpayer Cost
The Wrongful Denial Echo Chamber does not save money. It shifts costs from the insurer onto the public:
- A denied $55,000 iliac vein stenting surgery (85–90% five-year patency rate) triggered cascading wound care failures
- A 17-month delay in FDA-standard Apligraf wound treatment (PMA P950032S016, established 2000) allowed infection to progress until bone pathology showed demineralization described as "cuttable with a scalpel"
- When Apligraf was finally approved, it closed the wounds in two weeks — vindicating the standard UHC suppressed for 17 months
- The denied permanent prosthetic resulted in statistically preventable falls and the loss of physical capacity to protect an autistic child from danger
- Total taxpayer-funded cost: $1.1 million and climbing — on a case that began with a $55,000 denial